Mitral valve surgery combined with tricuspid valve repair improved 7-year event-free survival compared to percutaneous mitral valvuloplasty (95% vs 77%; P=0.05) in severe mitral stenosis.
Cohort (n=92)
Does mitral valve surgery combined with tricuspid valve repair improve clinical outcomes compared to percutaneous mitral valvuloplasty alone in patients with severe mitral stenosis and severe functional tricuspid regurgitation?
Mitral valve surgery combined with tricuspid valve repair is associated with better long-term event-free survival and greater improvement in tricuspid regurgitation compared to percutaneous mitral valvuloplasty alone in patients with severe mitral stenosis and severe functional tricuspid regurgitation.
Absolute Event Rate: 95% vs 77%
p-value: p=0.05
BACKGROUND: The persistence of significant tricuspid regurgitation (TR) after percutaneous mitral valvuloplasty (PMV) is known to be an independent predictor of adverse outcome in mitral stenosis (MS). However, it remains unclear whether mitral valve (MV) surgery combined with surgical correction of TR is the better treatment option than PMV in patients with severe MS and severe functional TR. METHODS AND RESULTS: We included a total of 92 consecutive patients (18 men, age 49+/-13 years) with severe MS and severe functional TR, who were potential candidates for PMV from 1997 to 2005, and the exclusion criteria were defined as the presence of left atrial thrombi, mitral regurgitation > or = grade 3, echo score > 10, and left ventricular ejection fraction (EF) < 35%. PMV was performed on 48 patients (PMV group), and MV surgery combined with tricuspid valve (TV) repair was performed on 44 patients (TVP group). The clinical events were defined as death, repeat surgical or percutaneous intervention, and readmission because of heart failure. There were no significant differences between the 2 groups in terms of gender, baseline EF, and baseline severity of pulmonary hypertension, but patients in the TVP group were older and had a higher echo score and a higher incidence of atrial fibrillation than those in the PMV group. During follow-up of 57+/-35 months, 2 deaths occurred in the TVP group, and there were 2 deaths, 7 cases of heart failure requiring surgical intervention in the PMV group. The difference of event rates between the 2 groups showed borderline significance (P=0.05), but no difference in mortality was observed. The estimated actuarial 7-year event-free survival rate was 77+/-8% in the PMV group and 95+/-3% in the TVP group. Severe TR was improved to mild or absent TR in 43 (98%) patients in the TVP group, and this was significantly higher than in the PMV group (22/48, 46%; P<0.001). In the TVP group, the right ventricle (RV) size was significantly decreased in 18 (90%) patients among 20 patients with preoperative significant RV enlargement. On stepwise multivariate logistic regression analysis, TVP group and baseline sinus rhythm were independent predictors for improvement of TR (P<0.001). CONCLUSIONS: TV repair combined with MV surgery was related to better clinical outcomes than PMV alone, and we recommend that this surgical option should be considered preferentially in severe MS with severe functional TR, especially if atrial fibrillation or enlarged RV is associated.
Song et al. (Mon,) conducted a cohort in Severe mitral stenosis with severe functional tricuspid regurgitation (n=92). Mitral valve surgery combined with tricuspid valve repair vs. Percutaneous mitral valvuloplasty was evaluated on Actuarial 7-year event-free survival (p=0.05). Mitral valve surgery combined with tricuspid valve repair improved 7-year event-free survival compared to percutaneous mitral valvuloplasty (95% vs 77%; P=0.05) in severe mitral stenosis.